Correlations between \textit{ISL1} rs1017 polymorphism and congenital heart disease risk

A PRISMA-compliant meta-analysis

Zhaohong Ding, MD\textsuperscript{a,b}, Wenke Yang, MD\textsuperscript{c}, Kang Yi, MD\textsuperscript{a,b}, Yunhan Ding, MD\textsuperscript{c}, Dan Zhou, MD\textsuperscript{a}, Xiaodong Xie, PhD\textsuperscript{e,f}, Tao You, MD\textsuperscript{a,b,*}

Abstract

\textbf{Background:} \textit{ISL1} promotes cardiomyocyte differentiation and plays important roles in heart development. However, whether \textit{ISL1} rs1017 polymorphism is associated with the congenital heart disease (CHD) risk remains controversial.

\textbf{Methods:} Five database including PubMed, Cochrane Library, ISI Web of Science, CNKI, and Wan Fang were searched by using key words “Insulin Gene Enhancer Protein ISL1” and “Single Nucleotide Polymorphism,” and “Congenital Heart Disease.” Five relative articles including 6 independent studies containing 2132 cases and 3812 controls were finally recruited to our study. Meta-analyses were performed by pooling odds ratios (ORs) and 95\% confidence interval (CI) from included studies using STATA 12.0 software.

\textbf{Results:} The associations between \textit{ISL1} rs1017 polymorphism and the risk of CHD were statistically significant under the allele model (T vs A; OR: 1.421; 95\% CI: 1.072–1.882), heterozygous model (AT vs AA; OR: 1.342; 95\% CI: 1.019–1.767), and dominant model (AT+TT vs AA; OR: 1.466; 95\% CI: 1.059–2.028). Sensitivity analysis indicated that the results were not stable. Subgroup analysis demonstrated that associations were found in Caucasians under the allele model and the heterozygous model ($P < .05$), but not the dominant model ($P > .05$).

\textbf{Conclusion:} In summary, our meta-analysis results suggest that the T allele of \textit{ISL1} rs1017 is a risk factor for CHD. However, further studies based on large sample size and multi-ethnic population should be conducted to further prove this correlation.

\textbf{Abbreviations:} CHD = congenital heart disease, CI = confidence interval, HWE = Hardy–Weinberg equilibrium, MAF = minor allele frequency, OR = odds ratio, SNP = single nucleotide polymorphism.

\textbf{Keywords:} congenital heart disease, \textit{ISL1}, meta-analysis, single nucleotide polymorphism

1. Introduction

Congenital heart disease (CHD) is a common birth malformation defined by heart or intrathoracic great vessels structural defects that occur before birth and affect normal function of septum, valves, and the vascular drainage of the cardiac segments.[1,2] CHD is the leading non-infectious cause of infant death, with a mortality rate of >25\%.[3] Chromosome abnormalities and teratogen exposure account for about 20\% of CHD cases, the etiology of the remaining non-syndromic, sporadic CHD involves a complicated interaction between environmental factors and genetic factors that still remains unclear.[4]

\textit{ISL1} is a LIM homeodomain transcription factor which was first reported as a regulator of insulin expression. During embryogenesis, \textit{ISL1} is widely expressed in different cell lineages and plays an essential role in the organogenesis.[5,6] For early heart development, \textit{ISL1} serves as a marker for the cardiac progenitor cells in the second heart field, which will further differentiate to the cells of the right ventricular, right atrium, outflow tract, and pacemaker.[7–9] Previous studies have revealed that \textit{ISL1}, by itself or through cooperating with a variety of transcription factors including \textit{HAND2}, \textit{TBX20}, \textit{GATA4}, and \textit{FOXH1}, regulates downstream genes transcription, such as \textit{Mef2c}, \textit{Myocd}, \textit{Nkx2–5}, \textit{SHH}, \textit{FGF10}, and \textit{BMP4}, which are involved in cardiac differentiation and development.[7,10–14] Moreover, \textit{Isil} mutation are shown to be associated with cardiac defect phenotype in the mouse and zebrafish.[12,15] Given that \textit{ISL1} plays pivotal roles in cardiac development, it is considered to be a potential genetic factor that is involved in the development of non-syndromic, sporadic CHD.

Human \textit{ISL1} gene is located on chromosome 5q11.1. Two rare variants in the coding region of \textit{ISL1} including a deletion
mutation and a nonsense mutation (p.E137X) have been reported to contribute to CHD.[16,17] Several ISL1 polymorphisms have been reported, of which the common single nucleotide polymorphism (SNP) rs1017 in the 3′ untranslated region (3′UTR) of ISL1 gene has been identified to be associated with the risk of CHD.[15–22] Previously, Stevens et al.[18] evaluated the correlation between ISL1 rs1017 polymorphism and CHD risk in European white population. In addition, several studies suggested that the T allele of rs1017 contribute to the risk of CHD in Chinese population.[20–22] However, Xue et al.[19] were unable to identify the correlation between the ISL1 rs1017 polymorphism and CHD risk in Chinese population. Given that the results of previous studies remain inconclusive and controversial, we conducted this meta-analysis to further evaluate the correlation between ISL1 rs1017 polymorphism and CHD susceptibility.

2. Materials and methods

2.1. Literature search

Five databases including PubMed, Cochrane Library, ISI Web of Science, CNKI, and Wan Fang until February 20, 2019 were searched to identify relevant studies using the following search terms: [Insulin Gene Enhancer Protein ISL1 or ISL LIM Homeobox 1 or ISLET1 or ISL1 or rs1017] and (“Polymorphism, Single Nucleotide”[Mesh] or SNP or SNPs or polymorphism or mutation or variant or variation or allele or genotype), and (“Heart Defects, Congenital”[Mesh] or congenital heart disease or CHD or birth defect or heart abnormality or malformation of heart). There was no restriction on publication date and language. The references of previous articles were screened manually for potential studies.[16–22] This meta-analysis was based on previously published studies, the ethical approval and the patient consent were not necessary.

2.2. Inclusion and exclusion criteria

Studies meeting the following criteria were included: estimating the association between ISL1 rs1017 polymorphism and CHD risk. Case-control studies. Genotyping data of samples are available. The distribution of genotypes in the controls was consistent with Hardy–Weinberg equilibrium (HWE). The exclusion criteria were as follows: lack of control population; lack of eligible genotype frequencies; duplicated publications, and controls were not consistent with HWE.

2.3. Data extraction

Two investigators extracted data from all included publications independently according to the inclusion and exclusion criteria and the third investigator adjudicated the conflicting information until consensus was reached on every item. The following characteristics were collected from each original study: last name of the first author, year of publication, country and ethnicity of studied population, sample size of cases and controls, genotyping method, frequencies of allele or genotype in cases and controls, and P value for HWE test in controls.

2.4. Statistical analysis

The goodness-of-fit Chi-square test for Hardy–Weinberg equilibrium was performed in control group from each study. P value >.05 was considered as in accordance with Hardy–Weinberg equilibrium. The correlation between ISL1 rs1017 polymorphism and CHD susceptibility was tested by odds ratios (ORs) analysis and the corresponding 95% confidence intervals (CIs) in 5 genetic models including allele model (T vs A), homozygous model (TT vs AA), heterozygous model (AT vs AA), dominant model (AT+TT vs AA), and recessive model (TT vs AT+AA). Bonferroni correction was used for homozygous model and heterozygous model. Subgroup analysis was performed based on different ethnicities. Heterogeneity among studies was assessed using the Chi-square-based Q test and I² test, and the heterogeneity was considered significant at P <.10 or I² > 50%. If the P value for heterogeneity tests was >.10 (P >.10) or I² <.50%, a fixed effects model was used to calculate the pooled OR. Otherwise, a random effects model was used. Sensitivity analysis was performed by removing one study at a time to assess the effect of each study on the combined ORs. Publication bias was explored by Begg funnel plot and Egger test, and P <.05 was considered as a significant publication bias. All analyses were performed by STATA 12.0 software.

3. Results

3.1. Characteristics of the studies

The study screening process was shown in Fig. 1. Initially, a total number of 153 studies were identified from the databases or by manual search. Among of them, 144 studies were excluded as they were either duplicated studies, reviews, inadequate data, or irrelevant to the association of rs1017 polymorphism and CHD. The full text of the remaining 9 potential articles were fully examined and 3 were eliminated because of the reduplicative data. Furthermore, one study was excluded due to the inconsistency of the distribution of genotypes with HWE (P<.05).[23] Since the article of Stevens et al.[18] included 2 independent studies, as a result, a total number of 5 articles including 6 independent studies were identified according to the inclusion criteria.[18–22] Finally, this meta-analysis included 2132 cases and 3812 controls and the available detailed characteristics were described in Table 1.

3.2. Meta-analysis

Overall, statistically significant heterogeneity (P <.10, I² > 50%) was observed among these included studies, therefore the random effects models were used for the following analysis. Our meta-analysis demonstrated that ISL1 rs1017 polymorphism significantly correlated with the increased risk of CHD under the allele model (T vs A; OR: 1.421; 95% CI: 1.072–1.882), heterozygous model (AT vs AA; OR: 1.342; 95% CI: 1.019–1.767), and dominant model (AT+TT vs AA; OR: 1.466; 95% CI: 1.059–2.028). After Bonferroni correction, the results of heterozygous model and dominant model are not statistically significant, which may due to the sample size in the study pool was limited. Moreover, no statistically significant correlation was identified between the rs1017 polymorphism and the risk of CHD under the homozygous model (TT vs AA; OR: 1.656; 95% CI: 0.923–2.974) or recessive model (TT vs AT+AA; OR: 1.393; 95% CI: 0.906–2.142).

Subgroup analysis was performed based on ethnicity. No significant correlation was observed between the rs1017 polymorphism and the CHD risk in Asians. However, statistically significant associations were found in the allele model (T vs A; OR: 1.470; 95% CI: 1.048–2.062), heterozygous model (AT vs TT; OR: 1.280; 95% CI: 0.968–1.693), dominant model (AT+TT vs AA; OR: 1.555; 95% CI: 1.114–2.176), and recessive model (TT vs AT+AA; OR: 1.244; 95% CI: 0.971–1.623).
Table 1
Main characteristics of the included studies.

| Study   | Year | Country | Ethnicity | Genotyping method   | Sample size (case/control) | Genotype frequency in cases (AA/AT/TT) | Genotype frequency in controls (AA/AT/TT) | \( P_{\text{HWE}} \) of controls | MAF |
|---------|------|---------|-----------|---------------------|---------------------------|----------------------------------------|------------------------------------------|--------------------------------|-----|
| Stevens* | 2010 | America | Caucasian | Illumina SNP array  | 83/425                    | 21/43/19                               | 182/192/51                               | .97                           | .369 |
| Stevens* | 2010 | America | Caucasian | Illumina SNP array  | 265/1445                  | 91/128/46                              | 591/672/182                              | .67                           | .367 |
| Xue      | 2012 | China   | Asian     | TaqMan assay        | 1003/1012                 | 740/244/19                            | 771/223/18                              | .69                           | .134 |
| Mu       | 2013 | China   | Asian     | Sequencing          | 35/30                     | 20/13/2                               | 26/4/0                                  | .70                           | .162 |
| Luo      | 2014 | China   | Asian     | PCR-RFLP            | 233/288                   | 172/53/8                              | 248/40/0                                | .21                           | .531 |

T allele is the minor allele of rs1017.
HWE = Hardy-Weinberg equilibrium, MAF = minor allele frequency, \( P_{\text{HWE}} \) = \( P \) value for HWE in control.
PCR-RFLP = polymerase chain reaction–restriction fragment length polymorphism.
*In the study by Stevens, subjects from the stage 1 and the stage 2.
Moreover, the study of Lang et al.\cite{21} significantly skewed the pooled OR values for the rs1017 polymorphism in the 5 applied genetic models. After exclusion of Lang et al.\cite{21} study, the pooled OR values for the whole population were reversed for the homozygous model (TT vs AA; OR: 2.043; 95% CI: 1.139–3.663) and recessive model (TT vs AT+AA; OR: 1.636; 95% CI: 1.062–2.519), while the corresponding pooled OR values remained unchanged in any genetic models in Asian subgroup. The possible reason for greater effect of Lang et al.\cite{21} study was that it was the only study with a difference greatly from other studies in terms of minor allele frequency (MAF) (Table 1). Moreover, according to the Genome Aggregation Database, the minor T allele frequency of rs1017 is 0.157 and 0.380 in the East Asian and the American population, respectively.

3.3. Sensitivity analyses and publication bias

Due to the significant heterogeneity across studies, the influence of a single study on the overall meta-analysis results was evaluated by deleting one study at a time. Sensitivity analysis showed that the overall findings were not robust to potentially influential decisions by any of the included studies (Fig. 3). Moreover, the study of Lang et al.\cite{21} significantly skewed the pooled OR values for the rs1017 polymorphism in the 5 applied genetic models. After exclusion of Lang et al.\cite{21} study, the pooled OR values for the whole population were reversed for the homozygous model (TT vs AA; OR: 2.043; 95% CI: 1.139–3.663) and recessive model (TT vs AT+AA; OR: 1.636; 95% CI: 1.062–2.519), while the corresponding pooled OR values remained unchanged in any genetic models in Asian subgroup. The possible reason for greater effect of Lang et al.\cite{21} study was that it was the only study with a difference greatly from other studies in terms of minor allele frequency (MAF) (Table 1). Moreover, according to the Genome Aggregation Database, the minor T allele frequency of rs1017 is 0.157 and 0.380 in the East Asian and the American population, respectively.

Begg funnel plot and Egger test were performed to assess the publication bias of the included studies. The Begg test showed no publication bias existed, while the Egger test suggested that publication bias was found in both the allele model (T vs A) for the whole population (T=3.14, P=0.033) and the homozygous model (TT vs AA) in Asian subgroup (T=5.05, P=0.037)

**Table 2**

Meta-analysis of published association between the ISL1 rs1017 polymorphism and CHD risk.

| Type (No. of studies) | OR (95% CI) | Z | P | Test of heterogeneity | Analysis model | P<, % | P< | Egger test<sup>1</sup> | Begg test<sup>1</sup> |
|-----------------------|-------------|---|---|-----------------------|-------------|------|----|-------------------|-------------------|
| Overall (6)           |             |   |   |                       |             |      |    |                   |                   |
| T VS A                | 1.421 (1.072–1.882) | 2.44 | .015 | 85.0 | <.001 | Random | 3.14 | .025 | 1.88 | .060 |
| AT VS AA              | 1.342 (1.019–1.767) | 2.10 | .036 | 68.1 | .008 | Random | 2.36 | .077 | 1.13 | .260 |
| TT VS AA              | 1.656 (0.923–2.974) | 1.69 | .091 | 76.7 | .001 | Random | 1.84 | .139 | 0.75 | .452 |
| AT+TT VS AA           | 1.466 (1.059–2.028) | 2.31 | .021 | 79.2 | <.001 | Random | 2.39 | .075 | 0.75 | .452 |
| TT VS AT+AA           | 1.393 (0.906–2.142) | 1.51 | .131 | 66.5 | .011 | Random | 2.10 | .103 | 0.38 | .707 |
| Asians (4)            |             |   |   |                       |             |      |    |                   |                   |
| T VS A                | 1.431 (0.944–2.171) | 1.69 | .091 | 87.7 | <.001 | Random | 2.52 | .128 | 1.02 | .308 |
| AT VS AA              | 1.322 (0.887–1.971) | 1.37 | .171 | 75.9 | .006 | Random | 1.41 | .294 | 0.34 | .734 |
| TT VS AA              | 1.284 (0.586–2.813) | 0.62 | .532 | 61.4 | .051 | Random | 5.05 | .037 | 1.02 | .308 |
| AT+TT VS AA           | 1.423 (0.806–2.260) | 1.49 | .135 | 83.6 | <.001 | Random | 1.46 | .282 | 0.34 | .734 |
| TT VS AT+AA           | 1.181 (0.620–2.251) | 0.51 | .613 | 51.1 | .105 | Random | 3.40 | .077 | 1.02 | .308 |
| Caucasian (2)         |             |   |   |                       |             |      |    |                   |                   |
| T VS A                | 1.470 (1.048–2.062) | 2.23 | .026 | 68.5 | .075 | Random | -    | -    | 0.00 | 1.000 |
| AT VS AA              | 1.365 (1.056–1.766) | 2.37 | .018 | 49.0 | .162 | Fixed  | -    | -    | 0.00 | 1.000 |
| TT VS AA              | 2.161 (1.127–4.146) | 2.32 | .020 | 63.9 | .096 | Random | -    | -    | 0.00 | 1.000 |
| AT+TT VS AA           | 1.623 (0.992–2.658) | 1.93 | .054 | 64.8 | .092 | Random | -    | -    | 0.00 | 1.000 |
| TT VS AT+AA           | 1.615 (1.102–2.383) | 3.10 | .002 | 23.6 | .253 | Fixed  | -    | -    | 0.00 | 1.000 |

D = confidence interval, OR = odds ratio.

<sup>1</sup> Random-effects model was used when the P for heterogeneity test < .05, otherwise the fixed-effect model was used.

<sup>2</sup> Egger test to evaluate publication bias. P < .05 is considered statistically significant.

<sup>3</sup> Begg test to evaluate publication bias. P < .05 is considered statistically significant.

<sup>4</sup> P value for the Q test.
Figure 3. Sensitivity analysis results. (A) Allele model (T vs A); (B) heterozygous model (AT vs AA); (C) homozygous model (TT vs AA); (D) dominant model (AT+TT vs AA); (E) recessive model (TT vs AT+AA).
Publication bias of the Egger test might be due to the small number of studies we included.

4. Discussion

As a member of the LIM homeodomain transcription factor, ISL1 is a marker molecule for cardiac progenitor cells and is highly expressed in fetal heart.[6–8] Studies have shown that ISL1 plays an important role in cardiomyocyte differentiation and heart development.[11–13] The abnormal expression of ISL1 may be one of the factors causing non-syndromic, sporadic CHD. Two loss-of-function mutations of ISL1 have been reported to contribute to the high risk of CHD.[16,17] In recent years, a number of studies have been carried out to explore the relationship between ISL1 rs1017 polymorphism and the CHD risk. Unfortunately, previous findings of ISL1 rs1017 polymorphism on CHD susceptibility were controversial and inconclusive.

To our knowledge, the present study was the first meta-analysis aimed to investigate the association between ISL1 rs1017 polymorphism and the CHD risk. Our study evaluated the available data including a total of 2132 cases and 3812 controls. The results showed that T allele of the rs1017 was associated with an increased risk of CHD in overall population. However, stratified analysis by ethnicity showed that the rs1017 polymorphism was associated with CHD risk in Caucasians population but not in Asians. The different results between Caucasians and Asians may be caused by the different genetic and environmental background in different races. Moreover, only 2 groups of Caucasians study data were included, further studies are needed to verify the results for Caucasians in current study.

In addition, we noticed that significant heterogeneity was found in all genetic models. After subgroup analyses by ethnicity, the heterogeneity still existed with a slight reduction. Meanwhile, other available variables including publication year, sample size, and genotyping method could not be considered as the source of the heterogeneity, suggesting the existence of other unknown factors influencing the heterogeneity among included studies. When considering the subtypes of CHD as a subgroup variable, 3 of included studies contain the variable data.[19,21,22] Unfortunately, only one study described accurate phenotype-genotype information for CHD subtypes,[21] and one set of available data may not be suitable for meta-analysis of CHD subtypes. Besides, the variables of patient’s background and disease history were not described in the included original studies. Next, sensitivity analysis by deleting one study at a time indicated that the pooled OR values were not robust. Among all the included studies, the study by Lang et al.[21] had the greatest effect on the pooled OR values under the homozygous model and recessive model. The heterogeneity became stable with a slight reduction after deleting the study. The study by Lang et al.[21] was recognized as one of the sources for heterogeneity. It was the only study with the differences greatly from other studies and databases in terms of minor allele frequency (MAF). No publication bias was identified by Begg test, while the Egger test result suggested the publication bias in the allele model in overall population and in the homozygous model in Asian subgroup. Given the small number of the included studies, the reliability of these 2 methods were limited. More evidence based on large sample size and multi-ethnicities are needed to support the conclusion.

The present meta-analysis reviewed the currently available data to investigate the correlation between ISL1 rs1017 polymorphism and the CHD risk, the results were more reliable than individual studies. However, some limitations in our study should still be pointed out. Firstly, the number of studies we have included was limited, from which the majority of the subjects were for Asian population. The available variables in those studies were also very limited. Secondly, sensitivity analysis revealed that the pooled OR values were not robust, the study by Lang et al had a significant effect on the pooled OR values. Significant heterogeneity and publication bias among studies were observed. The limited available variables hampered to further examine the source of heterogeneity. Thirdly, the current study only studies 1 polymorphism of ISL1, rs1017, the results might lack stability on the overall relationship, especially for non-syndromic, sporadic CHD caused by multiple factors.

In conclusion, this meta-analysis provided evidence that ISL1 rs1017 polymorphism might affect the susceptibility to CHD. Specifically, the T allele of rs1017 polymorphism might be a risk factor for CHD in the Caucasian population. Further multi-ethnic studies with lager sample size are required to clarify this relationship.

Author contributions

Conceptualization: Zhaohong Ding, Wenke Yang, Xiaodong Xie, Tao You.

Data curation: Zhaohong Ding, Wenke Yang, Kang Yi, Yunhan Ding, Dan Zhou.

Formal analysis: Zhaohong Ding, Wenke Yang, Kang Yi.

Funding acquisition: Tao You, Xiaodong Xie.

Investigation: Zhaohong Ding, Wenke Yang, Kang Yi, Yunhan Ding, Dan Zhou, Xiaodong Xie, Tao You.

Methodology: Zhaohong Ding, Wenke Yang, Kang Yi, Dan Zhou.

Software: Zhaohong Ding, Wenke Yang.

Visualization: Zhaohong Ding, Wenke Yang.

Validation: Kang Yi, Dan Zhou.

Supervision: Tao You, Xiaodong Xie.

Writing – original draft: Zhaohong Ding, Wenke Yang.

References

[1] Jackson BT. The pathogenesis of congenital cardiovascular anomalies. N Engl J Med 1968;279:80–9.
[2] Mitchell SC, Korones SB, Berendes HW. Congenital heart disease in 56,109 births. Incidence and natural history. Circulation 1971;43:323–32.
[3] Gilboa SM, Salemi JL, Nemnitch WN, et al. Mortality resulting from congenital heart disease among children and adults in the United States, 1999 to 2006. Circulation 2010;122:2254–63.
[4] Soomere R, Wilson JJ, Bentham J, et al. Contribution of global rare copy-number variants to the risk of sporadic congenital heart disease. Am J Hum Genet 2012;91:489–501.
[5] Biemar F, Argenton F, Schmidtke R, et al. Pancreas development in zebrafish: early dispersed appearance of endocrine hormone expressing cells and their convergence to form the definitive islet. Dev Biol 2001;230:189–203.
[6] Cai CL, Liang X, Shi Y, et al. Isl1 identifies a cardiac progenitor population that proliferate prior to differentiation and contributes a majority of cells to the heart. Dev Cell 2003;5:877–89.
[7] Laugwitz KL, Moretti A, Caron L, et al. Isl1 cardiovascular progenitors: a single source for heart lineages? Development 2008;135:193–205.
[8] Bu L, Jiang X, Martin-Puig S, et al. Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature 2009;460:113–7.
[9] Liang X, Zhang Q, Cattaneo P, et al. Transcription factor ISL1 is essential for pacemaker development and function. J Clin Invest 2015;125:3256–68.
[10] Dorn T, Goedel A, Lam JT, et al. Direct nkx2-5 transcriptional repression of isl1 controls cardiomyocyte subtype identity. Stem Cells 2015;33:1113–29.
[11] Golzio C, Havis E, Daubas P, et al. ISL1 directly regulates FGF10 transcription during human cardiac outflow formation. PLoS One 2012;7:e30677.
[12] Lin L, Bu L, Cai CL, et al. Isl1 is upstream of sonic hedgehog in a pathway required for cardiac morphogenesis. Dev Biol 2006;293:756–63.
[13] Takeuchi JK, Mileikovskaia M, Koshiba-Takeuchi K, et al. Tbx20 dose-dependently regulates transcription factor networks required for mouse heart and motoneuron development. Development 2005;132:2463–74.
[14] Itou J, Kawakami H, Quach T, et al. Isl1 regulates establishment of the posterior hindlimb field upstream of the Hand2-Shh morphoregulatory gene network in mouse embryos. Development 2012;139:1620–9.
[15] Colombo S, de Sena-Tomas C, George V, et al. Nlx genes establish second heart field cardiomyocyte progenitors at the arterial pole and pattern the venous pole through Isl1 repression. Development 2018;145: pii: dev161497.
[16] Osoegawa K, Schultz K, Yun K, et al. Haploinsufficiency of insulin gene enhancer protein 1 (ISL1) is associated with d-transposition of the great arteries. Mol Genet Genomic Med 2014;2:341–51.
[17] Ma L, Wang J, Li L, et al. ISL1 loss-of-function mutation contributes to congenital heart defects. Heart Vessels 2019;34:658–68.
[18] Stevens KN, Hakonarson H, Kim CE, et al. Common variation in ISL1 confers genetic susceptibility for human congenital heart disease. PLoS One 2010;5:e10855.
[19] Xue L, Wang X, Xu J, et al. ISL1 common variant rs1017 is not associated with susceptibility to congenital heart disease in a Chinese population. Genet Test Mol Markers 2012;16:679–83.
[20] Mu SY, Zhang HY. Association between two SNPs of ISL1 gene and congenital heart disease in children. Zhongguo Dang Dai Er Ke Za Zhi 2013;15:822–6.
[21] Lang J, Tian W, Sun X. Association between ISL1 variants and susceptibility to ventricular septal defect in a Chinese cohort. Mol Diagn Ther 2013;17:101–6.
[22] Luo ZL, Sun H, Yang ZQ, et al. Genetic variations of ISL1 associated with human congenital heart disease in Chinese Han people. Genet Mol Res 2014;13:329–38.
[23] Cresci M, Vecoli C, Foffa I, et al. Lack of association of the 3’-UTR polymorphism (rs1017) in the ISL1 gene and risk of congenital heart disease in the white population. Pediatr Cardiol 2013;34:938–41.